 |
|
|
|
prIME Oncology invites you to view exciting news released from the 2010 Oncology Annual Meeting
in Chicago.
|
|
|
 |
|
12 JUNE 2010
|
| |
|
This expert interview with Hagop Kantarjian, MD, from The University of Texas M.D. Anderson Cancer Center in Houston, Texas; Julie Vose, MD, from the University of Nebraska Medical Center in Omaha, Nebraska; and Aristoteles Giagounidis, MD, PhD, from St. Johannes Hospital in Duisburg, Germany, discusses the topics of lymphoma, multiple myeloma, and CML focusing on the following data releases:
#8004: Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy
#8017: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104
#8018: Lenalidomide maintenance after transplantation for myeloma
#8021: Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study
#LBA6500: Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study
#6501: Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year
|
| |
|
Click to view the Expert Interview with Hagop Kantarjian, MD; Julie Vose, MD; and Aristoteles Giagounidis, MD, PhD 
Click here to complete the post-test online |
 |
|
8 JUNE 2010
|
| |
|
This expert interview with Dean Bajorin, MD, from Memorial Sloan-Kettering Cancer Center in New York, New York, and Lee Lokey, MD, from prIME Oncology in Atlanta, Georgia, discusses the topic of genitourinary malignancies focusing on the following data releases:
#LBA4507: A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer
#4508: Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC)
#CRA4504: Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633)
#4517: Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004)
|
| |
|
View an expert interview and opinion with Dean Bajorin, MD, and Lee Lokey, MD
Click here to complete the post-test online |
 |
|
9 JUNE 2010
|
| |
|
This expert interview with Lisa Carey, MD, from the University of North Carolina Chapel Hill in Chapel Hill, North Carolina, and William J. Gradishar, MD, from Northwestern University in Chicago, Illinois, discusses the topic of breast cancer focusing on the following data releases:
#508: Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor (PAM50) for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial
#533: Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer
#CRA1004: A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane
#1005: A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC)
|
| |
|
View an expert interview and opinion with Lisa Carey, MD, and William J. Gradishar, MD
Click here to complete the post-test online |
 |
|
8 JUNE 2010
|
| |
|
This expert interview with Sanjiv Agarwala, MD, from St. Luke’s Cancer Center in Bethlehem, Pennsylvania, and Vernon Sondak, MD, from the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, discusses the topic of melanoma focusing on the following data releases:
#4: A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma
#8509: Re-induction with ipilimumab, gp100 peptide vaccine, or a
combination of both from a phase III, randomized, double-blind,
multicenter study of previously treated patients with unresectable stage
III or IV melanoma
#8504: E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma
#LBA8512: A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma
|
| |
|
View an expert interview and opinion with Sanjiv Agarwala, MD, and Vernon Sondak, MD
Click here to complete the post-test online |
 |
|
7 JUNE 2010 |
| |
|
This expert interview with Gini Fleming, MD, from the University of Chicago Medical Center in Chicago, Illinois, and Mary Cianfrocca, DO, from Northwestern University in Chicago, Illinois, discusses the topic gynecologic malignancies, focusing on the following data releases:
#5003: A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA)
#5004: A gene expression profile of BRCAness that correlates with responsiveness to platinum and PARP inhibitors
#LBA5008: Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report
#LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study
|
| |
|
View an expert interview and opinion with Gini Fleming, MD, and Mary Cianfrocca, DO
Click here to complete the post-test online |
|
|
|
|
|
|
|
|
|
|
|
|
